The PALLAS reactor aims to provide ample radioisotopes for medical uses, such as diagnosis, therapy and (medical) nuclear research.
While the preparation for the project began in 2013, in light of the recent Commission decision on 2 billion EUR support, the way is clear for the completion of the PALLAS complex. According to the plans, the reactor is set to provide a comprehensive solution: apart from the production of the necessary isotopes, it also intends to provide the necessary infrastructure to efficiently deliver them to patients. The complex will consist of a reactor and logistics building, as well as a support building and a nuclear health centre. A chemistry laboratory will also operate in the reactor. According to the European Commission, the reactor will contribute “to ensuring security of supply of essential and live-saving medicines in line with the Pharmaceutical Strategy for Europe.” Once it is completed, It will replace the current High Flux Reactor (HFR), which was completed in 1961, and is situated in the Netherlands as well.
While the construction project is funded by the Netherlands, the European Commission’s approval was necessary to begin construction, after measure was deemed appropriate in accordance to EU state aid rules.
